Clinical lung cancer最新文献

{"title":"Comments on “Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma”","authors":"Jie Huang","doi":"10.1016/j.cllc.2024.08.001","DOIUrl":"10.1016/j.cllc.2024.08.001","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e446-e447"},"PeriodicalIF":3.3,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC","authors":"Alessandro Leonetti ,&nbsp;Veronica Cervati ,&nbsp;Roberta Minari ,&nbsp;Maura Scarlattei ,&nbsp;Michela Verzè ,&nbsp;Marianna Peroni ,&nbsp;Monica Pluchino ,&nbsp;Francesco Bonatti ,&nbsp;Fabiana Perrone ,&nbsp;Giulia Mazzaschi ,&nbsp;Agnese Cosenza ,&nbsp;Letizia Gnetti ,&nbsp;Paola Bordi ,&nbsp;Livia Ruffini ,&nbsp;Marcello Tiseo","doi":"10.1016/j.cllc.2024.07.016","DOIUrl":"10.1016/j.cllc.2024.07.016","url":null,"abstract":"<div><h3>Objectives</h3><div>Despite the outstanding results achieved by osimertinib for the treatment of advanced <em>EGFR</em>-mutated NSCLC, the development of resistance is almost inevitable. While molecular mechanism responsible for osimertinib resistance are being mostly revealed, the definition of predictive biomarkers is crucial in order to identify patients at higher risk of progression and optimize treatment strategy.</div></div><div><h3>Materials and Methods</h3><div>This is a prospective single-center study aimed to assess the potential role of liquid biopsy and 18F-FDG PET/CT derived metabolic parameters as noninvasive predictive biomarkers of osimertinib outcomes in advanced <em>EGFR</em>-mutated NSCLC patients. Patients underwent blood samples for ctDNA analysis at baseline, after 15 days and 1 month (t1) of osimertinib. 18F-FDG PET/CT was performed at baseline and after 1 month of osimertinib.</div></div><div><h3>Results</h3><div>Seventy-two advanced <em>EGFR</em>-mutated NSCLC patients treated with osimertinib in first (<em>n</em> = 63) and in second-line (<em>n</em> = 9) were prospectively enrolled. Baseline positive shedding status was significantly associated with a shorter progression-free survival (PFS) (9.5 vs. 29.2 months, <em>P</em> = .031). Early metabolic response (MR) led to improved PFS (16.8 vs. 5.5 months, <em>P</em> = .038) and OS (35.2 vs. 15.3 months, <em>P</em> = .047). Early MR was significantly correlated with subsequent radiologic response (<em>P</em> = .010). All 18F-FDG PET/CT baseline parameters were significantly related to baseline <em>EGFR</em> activating mutation allele frequency. Both clearance and no detection of <em>EGFR</em> at t1 were significantly associated with MR (<em>P</em> = .001 and <em>P</em> = .004, respectively).</div></div><div><h3>Conclusion</h3><div>Molecular and 18F-FDG PET/CT derived metabolic parameters might represent a useful tool to predict osimertinib outcome in advanced <em>EGFR</em>-mutated NSCLC patients.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e436-e445.e9"},"PeriodicalIF":3.3,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis","authors":"Felipe Soto-Lanza ,&nbsp;Lydia Glick ,&nbsp;Colin Chan ,&nbsp;Linda Zhong ,&nbsp;Nathaniel Wilson ,&nbsp;Saadia Faiz ,&nbsp;Saumil Gandhi ,&nbsp;Aung Naing ,&nbsp;John V. Heymach ,&nbsp;Vickie R. Shannon ,&nbsp;Maria Franco-Vega ,&nbsp;Zhongxing Liao ,&nbsp;Steven H. Lin ,&nbsp;Nicolas L. Palaskas ,&nbsp;Jia Wu ,&nbsp;Girish S. Shroff ,&nbsp;Mehmet Altan ,&nbsp;Ajay Sheshadri","doi":"10.1016/j.cllc.2024.07.017","DOIUrl":"10.1016/j.cllc.2024.07.017","url":null,"abstract":"<div><h3>Aims</h3><div>Despite known short-term mortality risk of immune checkpoint inhibitor (ICI) pneumonitis, its impact on 1-year mortality, long-term pulmonary function, symptom persistence, and radiological resolution remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 71 nonsmall cell lung cancer (NSCLC) patients treated with anti-PD(L)1 monoclonal antibodies between 2018-2021, who developed pneumonitis. Clinical and demographic covariates were collected from electronic medical record. Cox regression assessed associations with mortality, while logistic regression evaluated associations with persistent symptoms, hypoxemia, and radiological resolution.</div></div><div><h3>Results</h3><div>Steroid-refractory pneumonitis (hazard ratio [HR] = 15.1, 95% confidence interval [95% CI]:3.9-57.8, <em>P</em> &lt; .0001) was associated with higher 1-year mortality compared to steroid-responsive cases. However, steroid-resistant (odds ratio [OR] = 1.4, 95% CI: 0.4-5.1, <em>P</em> = .58) and steroid-dependent (OR = 0.4, 95% CI: 0.1-1.2, <em>P</em> = .08) pneumonitis were not. Nonadenocarcinoma histology (OR = 6.7, 95% CI: 1.6-46.6, <em>P</em> = .01), grade 3+ pneumonitis (OR = 4.6, 95% CI: 1.3-22.7, <em>P</em> = .03), and partial radiological resolution (OR = 6.3, 95% CI: 1.8-23.8, <em>P</em> = .004) were linked to increased pulmonary symptoms after pneumonitis resolution. Grade 3+ pneumonitis (OR = 8.1, 95% CI: 2.3-31.5, <em>P</em> = .001) and partial radiological resolution (OR = 5.45, 95% CI: 1.29-37.7, <em>P</em> = .03) associated with residual hypoxemia. Nonadenocarcinoma histology (OR = 3.6, 95% CI: 1.01-17.6, <em>P</em> = .06) and pretreatment ILAs (OR = 4.8, 95% CI: 1.14-33.09, <em>P</em> = .05) were associated with partial radiological resolution.</div></div><div><h3>Conclusions</h3><div>Steroid refractory pneumonitis increases 1-year mortality in NSCLC patients. Pretreatment ILAs may signal predisposition to fibrosis-related outcomes, seen as partial resolution, which in turn is associated with postresolution symptoms and residual hypoxemia. These findings offer insights for identifying patients at risk of adverse outcomes post-pneumonitis resolution.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 7","pages":"Pages 624-633.e2"},"PeriodicalIF":3.3,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage Ⅳ Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN Study","authors":"Jia Ma ,&nbsp;Min Peng ,&nbsp;Jianping Bi ,&nbsp;Qian Chen ,&nbsp;Guoliang Pi ,&nbsp;Ying Li ,&nbsp;Yi Peng ,&nbsp;Fanyu Zeng ,&nbsp;Chuangying Xiao ,&nbsp;Guang Han","doi":"10.1016/j.cllc.2024.07.005","DOIUrl":"10.1016/j.cllc.2024.07.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Lung cancer remains the most common malignancy and the leading cancer-related death among the elderly in China, which deserves more research attention. Immunotherapy combined with platinum-based doublet chemotherapy has been approved as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients who are devoid of specific gene mutations or fusions. Given that patients with NSCLC over the age of 65 typically exhibit declining organ function and physical condition, they often showed reduced tolerance for this rigorous treatment regimen. However, the KEYNOTE-042 study illuminated a promising pathway: in patients testing positive for programmed death-ligand 1 (PD-L1), immunotherapy alone has demonstrated a superior overall survival (OS) compared to platinum-based doublet chemotherapy. This suggests that moderating the intensity of chemotherapy and prioritizing immunotherapy may be a gentler alternative in elderly demographic.</div></div><div><h3>Patients and Methods</h3><div>This multicenter phase II clinical trial named UNICORN aimed to enroll 49 patients aged 65 and older, utilizing paclitaxel or nab-paclitaxel for those with squamous NSCLC, and pemetrexed for those diagnosed with lung adenocarcinoma. The treatment protocol entails 4 cycles of serplulimab plus chemotherapy followed by an extended regimen of serplulimab maintenance, spanning a total of 35 cycles. Primary endpoints of this study are progression-free survival (PFS), disease control rate (DCR) and the secondary endpoints are OS, objective control rate (ORR) and safety metrics.</div></div><div><h3>Conclusion</h3><div>This is the first study to evaluate the efficacy and safety of serplulimab combined with either paclitaxel or pemetrexed in elderly treatment-naïve patients with stage IV NSCLC whose PD-L1 are positive.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e389-e392"},"PeriodicalIF":3.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141847131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy","authors":"Ronald Damhuis ,&nbsp;Idris Bahce ,&nbsp;Suresh Senan","doi":"10.1016/j.cllc.2024.07.013","DOIUrl":"10.1016/j.cllc.2024.07.013","url":null,"abstract":"<div><h3>Background</h3><div>The Pacific trial reported improved outcomes when durvalumab was administered following concurrent chemoradiotherapy (CRT) for stage III NSCLC. Post-hoc subgroup analysis did not show favorable results for PD-L1 negative cases. We compared nationwide survival data with the trial outcomes, and evaluated the influence of PD-L1.</div></div><div><h3>Patients and methods</h3><div>Data from the Netherlands Cancer Registry were queried regarding patients with clinical stage III who underwent CRT, either by concurrent or sequential administration. Predictors for the use of consolidation treatment with durvalumab were evaluated by tabulations and logistic regression analysis. Overall survival (OS) was calculated from start of radiation or start of durvalumab and was stratified by PD-L1 score.</div></div><div><h3>Results</h3><div>Between 2017 and 2021, application of consolidation durvalumab increased from 2% to 21%, 40%, 57%, 62%, respectively. In the period 2020-2021, durvalumab use was more frequent among patients with younger age, concurrent CRT, better performance score and proton radiation, but was irrespective of PD-L1 score.</div><div>For patients receiving durvalumab (n = 1639), the 4-year OS was 53% overall (95%CI 50-57), and it was 56% (95%CI 52-60) after concurrent CRT. Four-year OS was considerably better for the PD-L1 subgroup ≧50% at 67% (95%CI 59-73), and it was similar for PD-L1 subgroups 0 and 1-49, at 51% (95%CI 42-58) and 46% (95%CI 39-54), respectively.</div></div><div><h3>Conclusion</h3><div>In real-world clinical practice, survival outcomes were equivalent to results from trial series. Overall survival in patients with negative PD-L1 was similar to the survival in patients with PD-L1 1-49, questioning the restrictions imposed by the European Medicines Agency.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages 683-689"},"PeriodicalIF":3.3,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)","authors":"Hayato Kawachi ,&nbsp;Motohiro Tamiya ,&nbsp;Yuko Oya ,&nbsp;Go Saito ,&nbsp;Yoshihiko Taniguchi ,&nbsp;Hirotaka Matsumoto ,&nbsp;Yuki Sato ,&nbsp;Taiichiro Otsuki ,&nbsp;Hidekazu Suzuki ,&nbsp;Yasushi Fukuda ,&nbsp;Satoshi Tanaka ,&nbsp;Yoko Tsukita ,&nbsp;Junji Uchida ,&nbsp;Yoshihiko Sakata ,&nbsp;Yuki Nakatani ,&nbsp;Ryota Shibaki ,&nbsp;Daisuke Arai ,&nbsp;Asuka Okada ,&nbsp;Satoshi Hara ,&nbsp;Koichi Takayama ,&nbsp;Kazumi Nishino","doi":"10.1016/j.cllc.2024.07.014","DOIUrl":"10.1016/j.cllc.2024.07.014","url":null,"abstract":"<div><h3>Background</h3><div>The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent treatment strategy for this clinical population.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively enrolled 523 consecutive patients with LA-NSCLC treated with CRT and analyzed the treatment outcomes of subsequent therapy after progression following CRT and consolidative durvalumab therapy. Patients who received tyrosine kinase inhibitors as subsequent therapy were excluded.</div></div><div><h3>Results</h3><div>Out of 122 patients who received subsequent chemotherapy, 55% underwent platinum-based, 25% non-platinum-based, and 20% immune checkpoint inhibitor (ICI)-containing therapies. In the platinum-based group, patients with a durvalumab-progression-free survival (Dur-PFS) ≥ 1 year had a significantly longer median subsequent therapy-PFS (SubTx-PFS) than those with Dur-PFS &lt; 1 year (13.2 months vs. 4.7 months; hazard ratio, 0.45; 95% confidence interval, 0.21–0.97; <em>P</em> = .04). Furthermore, among patients receiving non-platinum-based chemotherapy, the median SubTx-PFS was longer in the combined with angiogenesis inhibitor group than in the without group, although the difference was not statistically significant. No significant difference of SubTx-PFS was observed between the reason for durvalumab discontinuation and the outcomes of ICI-containing therapy.</div></div><div><h3>Conclusion</h3><div>In clinical practice, platinum-based chemotherapy rechallenge is frequently employed following progression subsequent to CRT and consolidative durvalumab therapy for LA-NSCLC. Optimal treatment strategies may consider Dur-PFS and angiogenesis inhibitor feasibility. Further research is warranted to identify clinical biomarkers that can help identify patients who would benefit from ICI rechallenge.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 7","pages":"Pages 643-652.e4"},"PeriodicalIF":3.3,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer","authors":"Amanda Reyes ,&nbsp;Michelle Afkhami ,&nbsp;Erminia Massarelli ,&nbsp;Jeremy Fricke ,&nbsp;Isa Mambetsariev ,&nbsp;Xiaochen Li ,&nbsp;Giovanny Velasquez ,&nbsp;Ravi Salgia","doi":"10.1016/j.cllc.2024.07.010","DOIUrl":"10.1016/j.cllc.2024.07.010","url":null,"abstract":"<div><h3>Background</h3><div>According to WHO, lung cancer is the leading cause of cancer-related death worldwide, but treatment has advanced in the last decade. The widespread use of Next Generation Sequencing has led to the discovery of several pathogenic mutations including RNA binding motif 10 (RBM10), a part of the spliceosome complex that regulates splicing of pre-mRNA.</div></div><div><h3>Patients and Methods</h3><div>Electronic medical records were utilized to create a database of patients (50 patients) seen from 2018-2023 with NSCLC and <em>RBM10</em> mutations, with appropriate IRB approval. For subgroup analysis, we separated into groups by rapid progression vs stable disease defined as progression-free survival earlier than respective clinical trials.</div></div><div><h3>Results</h3><div>From the analysis of treatment response the mutated <em>RBM10</em> population had a median PFS was 6.7 months compared to 13.9 in the wild-type RBM10 population controlled for driver mutations TP53 mutation had a higher representation in the RBM10 mutated rapid progression group than the stable disease group. The ZFHX3 mutation had a higher representation in the RBM10 mutated stable disease group.</div></div><div><h3>Conclusions</h3><div><em>RBM10</em> mutations were associated with aggressive disease with treatment progression faster than median durations of response. <em>RBM10</em> mutations with concurrent ZFHX3 and EGFR mutations were associated with more stable disease, while concurrent KRAS and TP53 predicted even more aggressive disease.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e411-e419"},"PeriodicalIF":3.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition","authors":"Fabian Acker ,&nbsp;Alexandra Klein ,&nbsp;Anna Rasokat ,&nbsp;Anna Eisert ,&nbsp;Anna Kron ,&nbsp;Petros Christopoulos ,&nbsp;Albrecht Stenzinger ,&nbsp;Jonas Kulhavy ,&nbsp;Horst-Dieter Hummel ,&nbsp;Cornelius F. Waller ,&nbsp;Anne Hummel ,&nbsp;Achim Rittmeyer ,&nbsp;Cornelia Kropf-Sanchen ,&nbsp;Heiner Zimmermann ,&nbsp;Alisa Lörsch ,&nbsp;Diego Kauffmann-Guerrero ,&nbsp;Maret Schütz ,&nbsp;Franziska Herster ,&nbsp;Franziska Thielert ,&nbsp;Melanie Demes ,&nbsp;Sebastian Michels","doi":"10.1016/j.cllc.2024.07.012","DOIUrl":"10.1016/j.cllc.2024.07.012","url":null,"abstract":"<div><h3>Purpose</h3><div>MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi). However, MET amplification has been inconsistently defined and frequently included both polysomy and true amplification.</div></div><div><h3>Methods</h3><div>This is a multicenter, real-world analysis in patients with disease progression on EGFR inhibition and MET copy number gain (CNG), defined as either true amplification (MET to centromere of chromosome 7 ratio [MET-CEP7] ≥ 2) or polysomy (gene copy number ≥ 5, MET-CEP7 &lt; 2).</div></div><div><h3>Results</h3><div>A total of 43 patients with MET CNG were included, 42 of whom were detected by FISH. Twenty-three, 7, and 14 received EGFRi/METi, METi, and SoC, respectively. Patients in the EGFRi/METi cohort exhibited a superior real-world clinical benefit rate, defined as stable disease or better, of 82% (95% confidence interval [CI], 60-95) compared to METi (29%, 4-71) and SoC (50%, 23-77). Median real-world progression-free survival was longer with EGFRi/METi with 9.8 vs. 4.3 months with METi (hazard ratio [HR], 0.19, 95% CI, 0.06-0.57) and 3.7 months with SoC (0.41, 0.18-0.91), respectively. Overall survival was numerically improved. Interaction analysis with treatment and type of CNG (amplification vs. polysomy) suggests that differences were exclusively driven by MET-amplified patients receiving EGFRi/METi (HR for OS, 0.09, 0.01-0.54).</div></div><div><h3>Conclusion</h3><div>In this real-world study, EGFRi/METi showed clinical benefit over METi and SoC. Future studies should focus on the differential impact of the type of MET CNG with a focus on true MET amplification as predictor of response.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages 672-682.e5"},"PeriodicalIF":3.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is Coming","authors":"Alice Avancini ,&nbsp;Diana Giannarielli ,&nbsp;Lorenzo Belluomini ,&nbsp;Federico Schena ,&nbsp;Michele Milella ,&nbsp;Sara Pilotto","doi":"10.1016/j.cllc.2024.07.015","DOIUrl":"10.1016/j.cllc.2024.07.015","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e431-e435"},"PeriodicalIF":3.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients","authors":"Prerana Jha ,&nbsp;Asim Joshi ,&nbsp;Rohit Mishra ,&nbsp;Ranendra Pratap Biswal ,&nbsp;Pooja Mahesh Kulkarni ,&nbsp;Sewanti Limaye ,&nbsp;Govind Babu ,&nbsp;Ullas Batra ,&nbsp;Prabhat Malik ,&nbsp;Rajiv Kumar ,&nbsp;Minit Shah ,&nbsp;Nandini Menon ,&nbsp;Amit Rauthan ,&nbsp;Moni Kuriakose ,&nbsp;Venkataramanan Ramachandran ,&nbsp;Vanita Noronha ,&nbsp;Prashant Kumar ,&nbsp;Kumar Prabhash","doi":"10.1016/j.cllc.2024.07.011","DOIUrl":"10.1016/j.cllc.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights for implementation of precision therapies.</div></div><div><h3>Methods</h3><div>We analyzed the genomic profiles of 325 lung adenocarcinoma and 81 lung squamous carcinoma samples from Indian patients using targeted sequencing of 50 cancer related genes. Correlations between genomic alterations and clinical characteristics were computed using statistical analyses. Additionally, we identified distinct features of Indian NSCLC genomes by comparison across different ethnicities.</div></div><div><h3>Results</h3><div>Our genomic analysis revealed several noticeable features of Indian NSCLC patients. Alterations in <em>EGFR</em> (45.8%), <em>TP53</em> (27.4%), <em>ALK</em> (11.4%) and <em>KRAS</em> (10.2%) were predominant in adenocarcinoma, with 68% eligible for targeted therapies. Squamous carcinoma exhibited prevalent alterations in <em>TP53</em> (40.7%), <em>PIK3CA</em> (17.3%), and <em>CDKN2A</em> (8.6%). We observed higher frequency of <em>EGFR</em> alterations (18.5%) in lung squamous carcinoma patients, significantly distinct from other ethnicities reported till date. Beyond established correlations, we observed 60% of PD-L1 negative squamous patients harbored TP53 alterations, suggesting intriguing therapeutic implications.</div></div><div><h3>Conclusions</h3><div>Our data revealed unique genomic variations of adenocarcinoma and squamous carcinoma patients, with significant indications for precision medicine and clinical practice of lung cancers. The study emphasizes the importance of clinical utility of NGS for routine diagnostics.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e420-e430.e20"},"PeriodicalIF":3.3,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}